Table 1 Comparison of general information and clinical characteristics of patients with AIS with good and poor prognosis.
From: Correlation analysis of inflammatory markers with the short-term prognosis of acute ischaemic stroke
Projects | Good prognosis (205) | Poor prognosis (101) | χ2/Z/t value | P-value |
|---|---|---|---|---|
Male, n (%) | 139 (67.8%) | 52 (51.5%) | 7.682 | 0.006 |
Age (\(\overline{\text{X}}\)±S) | 68.761 ± 10.763 | 75.327 ± 8.911 | − 5.3 | < 0.001 |
Risk factors, n (%) | ||||
High blood pressure | 147 (71.7%) | 80 (79.2%) | 1.988 | 0.159 |
Diabetes | 90 (43.9%) | 40 (43.9%) | 0.512 | 0.474 |
Coronary heart disease | 15 (7%) | 22 (21.8%) | 13.319 | < 0.001 |
Atrial fibrillation | 26 (12.7%) | 29 (28.7%) | 11.793 | < 0.001 |
Degree of internal carotid artery stenosis (> 50%) | 48 (23.4%) | 36 (35.6%) | 5.081 | 0.024 |
Plaque stability (unstable) | 133 (64.9%) | 68 (67.3%) | 0.180 | 0.671 |
TOAST subtypes | 26.529 | < 0.001 | ||
sad | 156 | 53 | ||
at | 29 | 15 | ||
ce | 17 | 30 | ||
sud | 3 | 3 | ||
Leukocytes, × 109/L, (\(\overline{\text{X}}\)±S) | 6.872 ± 1.932 | 7.466 ± 2.003 | − 2.498 | 0.013 |
Neutrophils, × 109/L, M (Q1, Q3) | 68.2 (52.9–82.2) | 73.05 (61.1–85.6) | − 5.265 | < 0.001 |
Lymphocytes, × 109/L, M (Q1, Q3) | 6.77 (5.7–8.08) | 7.7 (6.5–8.6) | − 4.528 | < 0.001 |
Mononuclear cells, × 109/L, (\(\overline{\text{X}}\)±S) | 0.518 ± 0.157 | 0.544 ± 0.18 | − 1.294 | 0.197 |
Platelet count, × 109/L (\(\overline{\text{X}}\)±S) | 203.771 ± 50.536 | 206.703 ± 59.576 | − 0.449 | 0.671 |
LDH, mmol/L, M (Q1, Q3) | 2.88 (2.53–3.48) | 2.87 (2.12–3.28) | − 0.117 | 0.907 |
HDH, mmol/L (\(\overline{\text{X}}\)±S) | 1.072 ± 0.233 | 1.108 ± 0.209 | − 1.325 | 0.186 |
Albumin, g/L, M (Q1, Q3) | 1.04 (0.94–1.22) | 1.1 (1–1.22) | − 0.743 | 0.457 |
Creatinine, µmol/L, M (Q1, Q3) | 39.2 (37–42) | 38.65 (35.725–40.5) | − 0.994 | 0.32 |
Albumin/creatinine, M (Q1, Q3) | 67.1 (55–78.9) | 68.65 (55–75.775) | − 0.395 | 0.693 |
ApoB, g/L, M (Q1, Q3) | 0.5657 (0.4959–0.7613) | 0.5797 (0.4793–0.7) | − 2.314 | 0.021 |
ApoA1, g/L, M (Q1, Q3) | 0.84 (0.74–0.98) | 0.66 (0.55–0.85) | − 2.459 | 0.014 |
ApoB/ApoA1, M (Q1, Q3) | 1.19 (1.07–1.39) | 1.3 (1.1075–1.41) | − 3.521 | < 0.001 |
Lipoproteins, mmol/L, M (Q1, Q3) | 0.7206 (0.5391–0.797) | 0.5633 (0.4594–0.6439) | − 0.97 | 0.332 |
Antitrypsin, mg/L, M (Q1, Q3) | 139 (61–238) | 149.5 (82–252.75) | − 2.003 | 0.045 |
Acidic glycoprotein, mg/L, M (Q1, Q3) | 108.1 (96.5–125.7) | 114.3 (97.1–132.75) | − 2.473 | 0.013 |
PLR, M (Q1, Q3) | 111.640 (85.475–145.901) | 136.158 (106.524–212) | − 5.002 | < 0.001 |
NHR, M (Q1, Q3) | 4.065 (3.076–4.876) | 4.820 (3.919–5.664) | − 3.447 | < 0.001 |
MLR, M (Q1, Q3) | 0.264 (0.219–0.357) | 0.36 (0.266–0.475) | − 5.746 | < 0.001 |
NLR, M (Q1, Q3) | 2.290 (1.652–3.349) | 3.637 (2.886–5.289) | − 6.974 | < 0.001 |
SII, M (Q1, Q3) | 447.552 (363.871–643.848) | 770.868 (597.277–1092.731) | − 7.172 | < 0.001 |
SIRI, M (Q1, Q3) | 1.133 (0.875–1.630) | 2.117 (1.312–2.868) | − 7.056 | < 0.001 |
CRP, M (Q1, Q3) | 5 (2.28–11) | 8.42 (3–17.1) | − 2.646 | 0.008 |
